About SetPoint Medical
SetPoint Medical is developing a bioelectronic medicine platform using a small implanted device that activates the body's natural Inflammatory Reflex and produces a systemic anti-inflammatory effect.
Missing: SetPoint Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
ESPs containing SetPoint Medical
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Bioelectronic neuromodulators alleviate symptoms and treat diseases by targeting and manipulating (with electrical currents) specific electrical circuits in the body. This approach has a broad array of applications ‚Äî from spinal cord stimulation for pain relief to tibial nerve stimulation for overactive bladders to vagus nerve stimulation for seizure prevention.
Missing: SetPoint Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing SetPoint Medical
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned SetPoint Medical in 2 CB Insights research briefs, most recently on Aug 6, 2020.
Expert Collections containing SetPoint Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
SetPoint Medical is included in 4 Expert Collections, including Game Changers 2018.
Game Changers 2018
Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
SetPoint Medical Patents
SetPoint Medical has filed 1 patent.
Neurotechnology, Vagus nerve, Electrotherapy, Neurological disorders, Implants (medicine)
Neurotechnology, Vagus nerve, Electrotherapy, Neurological disorders, Implants (medicine)
Latest SetPoint Medical News
Oct 13, 2022
The RESET-RA study is the first-of-its-kind study to evaluate vagus nerve stimulation for the treatment of rheumatoid arthritis. Charles Sternberg, Associate Editor10.13.22 The first participant has been enrolled in Stage 2 of SetPoint Medical’s RESET-RA pivotal study, which is evaluating SetPoint Medical's investigational platform technology for treatment of rheumatoid arthritis (RA) using vagus nerve stimulation to activate innate anti-inflammatory pathways. The company recently announced FDA approval for continuation to Stage 2 of the study based on outcomes from an interim data analysis. “We are committed to delivering on our mission of pioneering a better alternative for the treatment of chronic autoimmune diseases – one with potentially less immunosuppressive risk, and lower cost than drug therapy – starting with RA, a serious autoimmune condition that causes significant pain and disability,” said Murthy V. Simhambhatla, Ph.D., president and CEO of SetPoint Medical. “The enrollment of the first patient in Stage 2 of our pivotal trial is a significant milestone on our journey toward gathering additional clinical evidence to support FDA approval of this novel approach.” The study participant was enrolled by Leroy Pacheco, M.D., of the Albuquerque Center for Rheumatology. The procedure was performed by Heather Spader, M.D., and James Botros, M.D., at University of New Mexico Hospital in Albuquerque. “Stimulating the vagus nerve to control systemic inflammation offers a promising new way of treating patients with RA and other inflammation-mediated diseases,” said Dr. Pacheco, the site's rheumatologist principal investigator. “Many RA patients experience inadequate response or intolerance to biologic therapies and are looking for alternative treatment options. The RESET-RA study represents an opportunity to evaluate this investigational approach for these patients.” The SetPoint system has been granted FDA Breakthrough Device Designation for patients with RA who have incomplete response to, or are intolerant to, multiple biologic drugs. The system consists of a miniaturized stimulation device that is placed on the vagus nerve through a small incision on the left side of the neck during an outpatient procedure. Once surgically placed, the device is programmed to automatically deliver therapy on a preset schedule. About the Trial “RESET-RA is an innovative trial for the field of rheumatology and we are excited about our continued participation,” said Valarie Jackson, clinical research site director for Albuquerque Center for Rheumatology. “We enrolled multiple patients in Stage 1 of the study, and are looking forward to contributing more participants in the second stage of the study.” The RESET-RA study is the first-of-its-kind study to evaluate vagus nerve stimulation for the treatment of RA. The two-staged, multicenter, randomized, sham-controlled, double-blind pivotal study will enroll up to 250 patients at 40 sites across the United States. The study is designed to evaluate the safety and efficacy of SetPoint’s therapeutic platform in patients with moderate-to-severe RA who are incomplete responders or are intolerant to biologic or targeted synthetic disease modifying anti-rheumatic drugs (DMARDs). The primary efficacy endpoint is the proportion of patients achieving an ACR20 response (a composite measure of the effectiveness of arthritis treatments set forth by the American College of Rheumatology) in the treatment group compared to sham group at 12 weeks.
SetPoint Medical Web Traffic
SetPoint Medical Rank
SetPoint Medical Frequently Asked Questions (FAQ)
When was SetPoint Medical founded?
SetPoint Medical was founded in 2006.
Where is SetPoint Medical's headquarters?
SetPoint Medical's headquarters is located at 25101 Rye Canyon Loop, Santa Clarita.
What is SetPoint Medical's latest funding round?
SetPoint Medical's latest funding round is Loan - II.
How much did SetPoint Medical raise?
SetPoint Medical raised a total of $194.16M.
Who are the investors of SetPoint Medical?
Investors of SetPoint Medical include Runway Growth Capital, New Enterprise Associates, Lightstone Ventures, Shangbay Capital, Paycheck Protection Program and 11 more.
Who are SetPoint Medical's competitors?
Competitors of SetPoint Medical include NeuroPace, Verily Life Sciences, Theranica, Orchestra BioMed, Stimdia Medical, Cala Health, ALung Technologies, Lungpacer Medical, Saluda Medical, Cardionomic and 47 more.
Compare SetPoint Medical to Competitors
Relievant provides the underserved population with a low-risk therapy that can eliminate back pain while preserving other therapeutic options. The Company's Intracept System is a minimally invasive procedure that uses radiofrequency energy delivered through a small access tube into the vertebral body to ablate the Basivertebral nerve. The nerve, thought to significantly contribute to chronic low back pain, can no longer generate pain signals following ablation. The company was founded in 2004 and is based in Minneapolis, Minnesota.
Cala Health develops wearable neuromodulation therapies to deliver individualized peripheral nerve stimulation. It was founded in 2014 and is based in San Mateo, California.
Neuspera Medical is a medical device startup that leverages exclusively licensed mid-field powering techniques to engineer miniaturized injectable neuromodulation technologies, sometimes referred to as electroceuticals. Neuspera's implantable module is more than 100 times smaller than other neuromodulation devices and may substantially reduce implant procedure complexity, time, patient complication, and post-surgical pain. Neuspera Medical is committed to bringing forward implantable medical device technology that will improve lives of patients battling with chronic illness.
Theranica is a medical device company that develops advanced neuromodulation devices for migraine and other idiopathic pain conditions. It provides an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of episodic and chronic migraine in people aged 12 and older. The firm serves clients operating in the healthcare sector. It was founded in 2016 and is based in Netanya, Israel.
eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.
Noctrix Health is developing therapeutic wearables that empower patients to take control of their chronic medical conditions.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.